This trial is evaluating whether BMS-986207 will improve 4 primary outcomes and 11 secondary outcomes in patients with Lung Cancer. Measurement will happen over the course of Up to 25 months.
This trial requires 212 total participants across 3 different treatment groups
This trial involves 3 different treatments. BMS-986207 is the primary treatment being studied. Participants will be divided into 3 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
"Bms-986207 has shown significant antitumor activity in a xenograft model of human solid tumors. The drug shows modest activity against NSCLC. In contrast to previous studies, this study clearly demonstrates that OS is better than TTG for pretreatment and concurrent administration." - Anonymous Online Contributor
"Most patients with carcinoma of the lung were discharged from the hospital within 30 days after admission. There was no difference in the complication rate among patients receiving chemotherapy or supportive care alone. Recent findings suggest that the severity of lung cancer do not affect the outcome of hospitalized patients." - Anonymous Online Contributor
"In view of the high relapse rate and poor prognosis associated with the disease, it seems reasonable to conclude that only a small fraction of NSCLC patients can be effectively cured of their disease." - Anonymous Online Contributor
"Recent findings provides evidence that bms-986207 has antitumor activity in metastatic NSCLC patients with a high number of relapses, indicating that this drug could serve as a new option to treat these patients." - Anonymous Online Contributor
"Bms-986207 was often added to conventional chemotherapy regimens or combined with radiotherapy. It was not associated with significantly increased toxicity when compared with chemotherapy alone or concurrent radiotherapy +/- chemotherapy." - Anonymous Online Contributor
"The progress of cancer management has been very slow recently. There have been few new discoveries regarding the curing of carcinoma, non-small-cell lung; however, there have been a number of new therapies developed for improving treatment outcomes. These therapies include antibody-drug conjugates (ADCs), alkylating agents, monoclonal antibodies, proteasome inhibitors, and other biologic agents. Furthermore, there are numerous clinical trials investigating these treatments, where results will be published soon. Moreover, many of these treatments may help reduce the pain associated with carcinoma, non-small-cell lung. To find a clinical trial tailored to your condition, and optimal treatment, you may reach out to [Power(http://www." - Anonymous Online Contributor
"Recent findings indicate that BMS-986207 is a potent inhibitor of PDP-15 expression in NSCLC cells. In addition, these data suggest that BMS-986207 could potentially serve as an effective chemotherapeutic agent against NSCLC." - Anonymous Online Contributor
"The study confirms that age, sex, race, cigarette smoking, and family history are risk factors for lung cancer. In addition to this information, the study also highlights several significant findings regarding risk factors for lung cancer. First, race was found to be an important factor in determining risk among all smokers. For never-smokers, however, African Americans were 12 times more likely than whites to develop lung cancer. Second, women who had been diagnosed with breast cancer were 3 times more likely to develop lung cancer. Third, persons who have had a history of occupational exposure to asbestos were at increased risk of developing lung cancer. Finally, there was a strong association between tobacco use and lung cancer, especially among men." - Anonymous Online Contributor
"This report shows that BMS-986207 has been used in a wide-range of indications. In addition, this study illustrates how phase I and II clinical trials are designed to optimize patient populations for future clinical trials. Recent findings of these studies hopefully will help clinicians select patients most likely to benefit from treatment with BMS-986207 at this time." - Anonymous Online Contributor
"A substantial number of cancer patients with severe disease have little prospect of survival beyond 2 years. Although results from published clinical trials suggest that certain agents prolong survival, there is no compelling evidence that they improve comfort or quality of life. The primary goal of clinical research should be to improve outcomes for the large group of patients who do not benefit from current therapies." - Anonymous Online Contributor
"The long-term survival rates for carcinoma, non-small-cell lung were 80%. Surgeons should keep in mind that some patients with carcinoma, non-small-cell lung have prolonged survival even after complete resection." - Anonymous Online Contributor